State of Alaska Department of Revenue decreased its holdings in Xencor, Inc. (NASDAQ:XNCR – Free Report) by 3.2% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 39,736 shares of the biopharmaceutical company’s stock after selling 1,299 shares during the quarter. State of Alaska Department of Revenue owned approximately 0.07% of Xencor worth $992,000 as of its most recent SEC filing.
Several other institutional investors have also recently bought and sold shares of the business. Arizona State Retirement System raised its position in shares of Xencor by 3.1% during the first quarter. Arizona State Retirement System now owns 16,495 shares of the biopharmaceutical company’s stock worth $460,000 after acquiring an additional 492 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its stake in shares of Xencor by 6.3% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 9,682 shares of the biopharmaceutical company’s stock worth $270,000 after purchasing an additional 575 shares during the period. UBS Group AG grew its stake in shares of Xencor by 2.8% during the third quarter. UBS Group AG now owns 21,376 shares of the biopharmaceutical company’s stock worth $555,000 after purchasing an additional 581 shares during the period. Tower Research Capital LLC TRC grew its stake in shares of Xencor by 48.4% during the first quarter. Tower Research Capital LLC TRC now owns 2,438 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 795 shares during the period. Finally, Yousif Capital Management LLC grew its stake in shares of Xencor by 1.5% during the first quarter. Yousif Capital Management LLC now owns 53,465 shares of the biopharmaceutical company’s stock worth $1,426,000 after purchasing an additional 807 shares during the period.
Analyst Upgrades and Downgrades
A number of equities research analysts recently commented on the company. Piper Sandler lifted their price objective on Xencor from $42.00 to $45.00 in a research note on Monday, August 7th. StockNews.com assumed coverage on Xencor in a research note on Thursday, October 5th. They set a “sell” rating for the company. Finally, Wedbush reaffirmed an “outperform” rating and set a $37.00 price objective on shares of Xencor in a research note on Friday, August 4th. One equities research analyst has rated the stock with a sell rating and eleven have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $42.67.
Xencor Price Performance
XNCR stock opened at $18.95 on Tuesday. The stock has a market capitalization of $1.15 billion, a P/E ratio of -8.86 and a beta of 0.73. The business has a 50-day moving average of $21.26 and a 200-day moving average of $24.57. Xencor, Inc. has a fifty-two week low of $18.26 and a fifty-two week high of $38.20.
Xencor (NASDAQ:XNCR – Get Free Report) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.91) by $0.54. The company had revenue of $45.52 million during the quarter, compared to analysts’ expectations of $26.25 million. Xencor had a negative return on equity of 18.14% and a negative net margin of 112.46%. Xencor’s revenue for the quarter was up 50.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.57) earnings per share. Equities analysts expect that Xencor, Inc. will post -2.86 EPS for the current year.
Xencor Profile
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Featured Articles
- Five stocks we like better than Xencor
- Retail Stocks Investing, Explained
- Warren Buffett Stocks: What’s in Warren Buffett’s Portfolio?
- Investing In Preferred Stock vs. Common Stock
- Snack Maker Mondelez Int’l Is Down but Not Out
- What Are Dividends? Buy the Best Dividend Stocks
- Costco, Dollar General, Target Up As Market Turns Defensive
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.
